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Objective: To analyze the frequency and distribution of α-synuclein deposits in
progressive supranuclear palsy (PSP).
Methods: The brains of 25 cases of pathologically confirmed PSP were evaluated
with immunohistochemistry for α-synuclein and tau. Multiple immunofluorescent stains
were applied to analyze the expression of tau and α-synuclein aggregates in
catecholaminergic neurons. Patients’ clinical symptoms were retrospectively recorded.
Results: Deposits α-synuclein in the form of typical Lewy bodies (LBs) were only
found in two PSP cases (8%) that fulfilled the clinical subtype of PSP known as
Richardson’s syndrome (RS). LBs were present in the locus ceruleus (LC), substantia
nigra pars compacta (SNc), basal forebrain, amygdala and cingulated cortex in a
distribution mimicking that of Parkinson’s disease (PD). Triple-immunolabeling revealed
co-expression of α-synuclein and tau proteins in some tyrosine hydroxilase (TH)-positive
neurons of the LC and SNc.
Conclusions: There is no apparent clinical correlation between the presence of LBs in
PSP. Tau protein co-aggregate with α-synuclein in catecholaminergic neurons of PSP
brains suggesting a synergistic interaction between the two proteins. This is in keeping
with the current view of neurodegenerative disorders as “misfolded protein diseases”.
Keywords: neurodegenerative diseases, atypical parkinsonian disorders, lewy bodies, multiple immunolabeling
techniques, substantia nigra
Introduction
Aggregation of α-synuclein in the form of Lewy bodies (LBs) is the histopathological hallmark
of idiopathic Parkinson’s disease (PD) and dementia with LBs (DLB; Spillantini et al., 1997).
LBs are present in the 50% of Alzheimer’s disease brains (AD; Hamilton, 2000) but they are
less frequently found in other neurodegenerative diseases such as progressive supranuclear
palsy (PSP; Abhinav et al., 2011). At present it is well known that protein aggregation
phenomena represent a crucial pathobiological mechanism shared by neurodegenerative
diseases such AD, PD, PSP and Huntington disease. Accordingly, these diseases have often
been categorized as ‘‘misfolded protein diseases’’, since cross-seeding of misfolded proteins
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apparently underlies a number of pathological events
associated with different diseases (reviewed in Soto and
Estrada, 2008; Cuanalo-Contreras et al., 2013; Morales et al.,
2013).
PSP is the most common atypical parkinsonian disorder
and is clinically characterized by prominent postural
instability, vertical gaze supranuclear palsy, pseudobulbar
palsy, cognitive impairment and levodopa unresponsiveness
(Steele et al., 1964). The pathology of PSP is characterized
by the accumulation of abnormal tau protein within neurons
(neurofibrillary tangles) and glial cells (tufted astrocytes
and coiled bodies) in the brain. The distribution of tau
inclusions is mainly subcortical and the globus pallidus,
subthalamic nucleus and substantia nigra are severely
affected in most cases. Other subcortical nuclei are affected
to varying degrees and cases of severe cortical degeneration
have been also described (Litvan et al., 1996). Whether the
presence of LBs in PSP represents a normal aging process or
the coexistence with PD remains unclear (Uchikado et al.,
2006).
The aim of the present study was to analyze the density
and distribution of LBs in the brains of patients with PSP, to
investigate the clinicopathological correlation of this association
and to characterize the interaction of α-synuclein and tau in
cases of PSP with LBs by means of multiple immunolabeling
techniques.
Materials and Methods
Subjects
Twenty five cases (2005--2013) of pathologically confirmed
PSP according to the revised NINDS criteria (Litvan et al.,
1996) from the Navarra Biomed Brain Bank were studied.
The establishment and operational rules of Navarra Biomed
Bank are both under the supervision of a Local Clinical
Ethical Committee in keeping with current Spanish legislation
(Royal Decree 1716/2011). Informed written consent form
was obtained in all cases. The clinical features of those
cases with LBs were evaluated by retrospective review of
medical records. The distribution of LBs was assessed with the
Braak’s PD staging scheme (Braak et al., 2003). For control
purposes, the mesencephalon of two age-matched individuals
(both males) without any known type of neurological disease
were used.
Neuropathological Evaluation
The brains were dissected through the corpus callosum in
the sagittal plane. The left cerebral hemisphere was immersed
in a 10% saline solution of 10% formaldehyde for 4 weeks.
According to the recommendation guide proposed by BrainNet
Europe (Bell et al., 2008), multiple regions of the neocortex
were examined including frontal cortex (middle frontal gyrus),
superior temporal, inferior parietal, occipital and cingulate
cortex, entorhinal cortex, hippocampus, amygdala, basal nucleus
of Meynert, striatum, subthalamic nucleus, brainstem and
cerebellum.
Routine workflow included immunohistochemical staining
of 3--5 µm-thick paraffin-embedded sections, followed by
counterstaining with hematoxylin-eosin.
Immunohistochemistry
Formalin-fixed sections (3--5 mm-thick) were mounted on slides
and deparaffinized. After conducting a routine antigen retrieval
protocol, sections were incubated overnight with either a
mouse monoclonal antibody against α-synuclein (NCL-L-ASYN;
Leica Biosystems) or with a mouse monoclonal antibody anti-
human PHF-TAU (clone AT-8; Thermo Scientific). The reaction
product was visualized using an automated slide immunostainer
(Leica Bond Max) with Bond Polymer Refine Detection (Leica
Biosystems Newcastle Ltd).
For semiquantitative analysis LBs density and Lewy neurites
(LN) were scored as follows: 0 = absent, + = mild, ++ =
moderate, +++ = severe and ++++ = very severe (McKeith
et al., 2005). In the assessment LBs brainstem type and cortical
were included. A PD neuropathological stage was assigned
according to the staging scheme proposed by Braak. For this
measure only the distribution of LBs in any brain region was
taken into account instead of the LBs density.
Dual Colorimetric Immunohistochemistry
Briefly, a sequential dual immunostaining protocol was used
for the simultaneous visualization of α-synuclein and tau. The
colorimetric detection of α-synuclein was carried out firstly using
a Bond Polymer Refine DAB detection kit (Leica) resulting in a
brown precipitate. Next, the Bond Polymer Refine Red detection
kit (Leica) was used to visualize the expression of tau protein by
means of a red-colored precipitate.
Multiple Immunofluorescence and Confocal
Microscopy
Multiple immunofluorescent stains were carried out in coronal
sections through the mesencephalon comprising both the
substantia nigra pars compacta (SNc) and the locus ceruleus
(LC). Briefly, 5 mm-thick brain blocks were postfixed for 24 h in
a buffered solution containing 4% paraformaldehyde. Once fixed,
sections were cryoprotected with a solution made of 20% gelatin
and 2% dimethylsulphoxide (DMSO) in 0.1M PBS, pH 7.4. Next,
frozen coronal sections (40 µm-thick) were obtained in a sliding
microtome and collected in the cryoprotective solution as 5 series
of adjacent sections.
Free-floating sections were incubated in a cocktail of primary
antisera comprising 1:200 mouse anti-synuclein (Invitrogen,
Ref. 08-1215), 1:200 rabbit anti-Tau (Dako-Sigma, Ref. A0024)
and 1:50 goat anti-tyrosine hydroxilase (TH) (Santa Cruz, Ref.
Sc-7847) overnight at room temperature. Sections were then
incubated for 90 min at room temperature in a cocktail of
alexa-tagged secondary antibodies, comprising 1:200 Alexa488-
coupled donkey anti-mouse IgG (Invitrogen, A21202), Alexa546-
coupled donkey anti-rabbit IgG (invitrogen, Ref. A31572)
and Alexa 633-coupled donkey anti-goat IgG (Invitrogen,
Ref. A21082). Stained sections were finally mounted in
gelatine-coated slides, air dried at room temperature in the
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TABLE 1 | Density and distribution of Lewy bodies.
Age/Sex Brain weight Cc Hdg Ec A nbM SNc LC Rn DMVn PD Braak stage
84F 1050 LB + 0 ++ ++ 0 + +++ + + 4
LN 0 + 0 + + + ++ 0 +
73M 1200 LB + 0 + + + + +++ + N.A. 4
LN 0 + 0 0 + 0 + + N.A.
Abbreviations: A, amygdala; Cc, cingulate cortex; DMVn, dorsal motor vagal nucleus; Ec, entorhinal cortex; Hdg, hippocampus dentate gyrus; LC, locus ceruleus; N.A.,
not available; nbM, basal nucleus of Meynert; PD, Parkinson’s disease; Rn, raphe nucleus; SNc, substantia nigra pars compacta.
dark, dehydrated in toluene and mounted with Entellan
(Merck).
Sections were inspected in a Zeiss 510 META confocal laser-
scanning microscope. To ensure appropriate visualization of the
labeled structures and to avoid false positive results, the emission
from the argon laser at 488 nm was filtered through a band pass
filter of 505--530 nm and color-coded in green. The emission
following excitation with the helium laser at 543 nm was filtered
through a band-pass filter of 560--615 nm and color coded in light
blue. Finally, a long-pass filter of 650 nm was used to visualize
the emission from the helium laser at 633 nm and color coded
in red.
Results
Clinical Features of the PSP Patients
The first patient was an 84-year-old woman who underwent
consultation at the Neurology Department complaining
FIGURE 1 | Coronal section through the ventral mesencephalon
showing the obtained dual stain for α-synuclein (TH; brown) and tau
(red). At the level of the substantia nigra pars compacta (SNc), up to three
different types of melanin-containing neurons were observed, comprising
(i) brown-stained neurons containing Lewy bodies (LBs; arrows), (ii) red-stained
neurons with tau immunoreactivity (arrowheads); and (iii) neurons showing both
LBs and tau deposits (asterisks). Scale bar is 4,000 µm in (A); 200 µm in (B)
and 50 µm in the high-magnification insets shown in panels (C) and (D).
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of progressive gait unsteadiness, with postural imbalance
and frequent falls reported over the previous year. She
did not refer cognitive decline. Neurologic examination
revealed facial inexpressiveness and mild hypophonia.
Glabelar and sucking reflexes were present. Ocular motility
was normal, generalized bradykinesia and rigidity were
present with a rigid neck extension posture, deep tendon
reflexes were brisk, gait was slow and unsteady with
severe impairment of postural righting reflexes. Computed
cranial tomography showed moderate cortical atrophy.
A diagnosis of atypical parkinsonian disorder with early
gait impairment suggestive of possible PSP was established
and treatment with carbidopa/levodopa was initiated.
One year later she referred impossibility in rising from a
seated position and difficulty in language articulation. Her
gait disorder progressed and she was wheelchair bound.
Response to carbidopa/levodopa was absent. Moreover, a
mild reduction of up gaze was found during the clinical
examination. On subsequent visits, oculomotor disorder was
established with blepharospasm, apraxia of eyelid closing
and vertical gaze palsy. She died from aspiration pneumonia
related to dysphagia 4 years and 2 months after the first
visit.
The second patient was a 73 year old man complaining from
memory loss and reduced talkativeness. Neuropsychological
evaluation showed mild short-term memory loss, disturbance of
executive functions, word finding difficulties and perseverative
errors. The diagnosis of a lobar frontotemporal dementia
was suspected. Two years later he developed progressive gait
unsteadiness and frequent falls. On examination focal findings
included reduction of upgaze, dysphasic language and slowness
of gait with disequilibrium. A trial of carbidiopa/levodopa was
unsuccessful. The diagnosis of probable PSP was suspected.
On subsequent years he developed bulbar symptoms with
dysartria, dysphagia and a behavior disorder with irritability,
insomnia and occasional visual hallucinations (VH). He died
from aspiration pneumonia 3 years and 9 months after the first
visit.
FIGURE 2 | Coronal section through the dorsal pons at the level of the
Locus ceruleus (LC), stained for α-synuclein and tau. At the level of the
LC, up to three different types of melanin-containing neurons were observed,
comprising (i) brown-stained neurons containing Lewy bodies (LBs; arrows), (ii)
red-stained neurons with tau immunoreactivity (arrowheads); and (iii) neurons
showing both LBs and tau deposits (asterisks). Scale bar is 4,000 µm in
(A); 200 µm in (B) and 50 µm in the high-magnification insets shown in panels
(C) and (D).
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FIGURE 3 | Triple immunofluorescent detection of TH, α-synuclein and
tau, as observed in a control case (A--D) as well as in the SNc and LC
from a case diagnosed with PSP (E--L’). Neurons in the SNc from a control
case are only immunoreactive for TH (red channel), without any noticeable
immunoreactivity for tau and α-synuclein (A and C, respectively). When
considering PSP cases at the level of the SNc and besides some neurons
single-expressing TH (arrows), neurons containing both LBs and tau aggregates
(Continued)
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FIGURE 3 | Continued
were clearly visible (asterisk). The presence of dystrophic neurites positive for
α-synuclein is also often observed (arrowheads). The same holds true at the
level of the LC. Panels (I--L) are low-magnification photomicrographs showing
(i) TH+ neurons with tau aggregates (arrowheads), (ii) TH+ neurons with LBs
(arrows); and (iii) TH+ neurons containing both LBs and tau immunoreactivity
(asterisk). It is worth noting the presence of dystrophic neurites
immunoreactive for either tau or α-synuclein. Panels (I’,J’) are
high-magnification insets taken from (I--L) to better appreciate one TH+
neuron showing tau immunoreactivity and multiple LBs. Scale bar is 50 µm for
low-magnification photomicrographs and 12.5 µm for insets.
Histopathological Findings
The presence of α-synuclein aggregates was only found in
2 patients from our cohort comprising a total of 25 cases
available at our Navarra Biomed Brain Bank. In both cases
the immunohistochemical detection of phosphorilated tau
demonstrated numerous positive neuronal and glial fibrillary
inclusions including tufted astrocytes and coiled bodies, as well
as neuropil threads fulfilling the neuropathological criteria of
PSP (Hauw et al., 1994; Litvan et al., 1996) such as dystrophic
axons and neurites. The greatest concentration of tau pathology
was found in the SNc and in the LC. The subthalamic nucleus,
the dentate nucleus of the cerebellum and pontine nuclei
displayed a moderate density of tau pathology. Mild density of
tau deposits were found in the hippocampus/entorhinal cortex
(without a preferential layer distribution), putamen, pallidum
and amygdaloid complex. Neocortical sections showed rare tau-
positive glial and neuronal inclusions.
Regarding α-synuclein deposits, protein aggregates in the
form of LBs and LN were consistently found throughout the
brain stem, with particular high incidence at the level of the LC in
both cases, as shown in Table 1. Mild density of LBs and LN were
found in the motor dorsal vagal nucleus, raphe nucleus and SNc.
Case 1 showed moderate density of α-synuclein deposits in the
entorhinal cortex and amygdale while case 2 contained scattered
LBs and LN in those areas. Both cases displayed mild α-synuclein
deposits in the hippocampus dentate gyrus, cingulate cortex and
nucleus basalis of Meynert. No LBs nor LN were found in the
subthalamic nucleus, striatum, pallidum, thalamus or neocortical
regions.
When considering catecholaminergic nuclei such as the
SNc and the LC, the dual colorimetric detection of tau and
α-synuclein showed different types of neuromelanin-containing
neurons, comprising (i) neurons with tau deposits; (ii) neurons
with LBs (quite often with more than one LB); and (iii) neurons
with both types of aggregates, i.e., tau and LBs (Figures 1, 2).
These three types of neurons were also observed in the conducted
triple immunofluorescent stains, which also fully confirmed
the monoaminergic nature of these neurons by showing that
all these types of neurons were also positive for TH, both
at the level of the SNc and the LC (Figure 3). Furthermore,
it is also worth noting that a minimal number of TH+
neurons completely lacked any type of protein aggregates
(Figure 3).
Discussion
Here, LBs were found in 8% of PSP brains, a percentage similar to
what might be expected in series of age-matched normal controls
(Tsuboi et al., 2001). The frequency of LBs in our PSP population
was lower than in previous reports (Table 2). Besides case reports
describing the incidental presence of LBs in PSP (Mori et al.,
1986; Fearnley et al., 1991; Judkins et al., 2002; Abhinav et al.,
2011) the percentages of LBs in necropsy series of PSP-diagnosed
patients ranged between 10.7% to 31.5% (Tsuboi et al., 2001;
Mori et al., 2002; Uchikado et al., 2006; Keith-Rokosh and Ang,
2008).
In the two PSP cases of the present study, LBs were widely
distributed throughout the brainstem and cerebrum in a pattern
that looks like what can be expected in PD. These similarities on
the distribution of LBs comparing PD and PSP have also been
already reported, although some controversies remain, since it
has been described that LBs were only found in the amygdala
of PSP patients (similarly to AD brains) and not in neither
the SNc nor the LC nucleus (Tsuboi et al., 2001; Uchikado
et al., 2006). The two PSP patients described in this paper
presented clinical manifestations of the classical phenotype of
PSP, originally described by Richardson which accounts for the
most common clinical form of PSP. The Richardson’s syndrome
(RS) is characterized by an insidious onset and relentlessly
progressive postural instability and falls, gait disturbance,
supranuclear vertical gaze abnormalities, pseudobulbar palsy,
rigidity in extension and a dysexecutive syndrome (Williams
et al., 2005). The clinical significance of LBs cannot therefore
TABLE 2 | Studies analyzing the presence of Lewy bodies in progressive supranuclear palsy.
Reference N (%) α-synuclein Doble immunolabeling Neuronal colocalization
immunohistochemistry techniques of tau and α-synuclein
Abhinav et al. (2011) 1 Yes No -
Keith-Rokosh and Ang (2008) 4 (12,5) Yes No -
Uchikado et al. (2006) 29 (10,7) Yes Yes Yes
Judkins et al. (2002) 1 Yes No -
Mori et al. (2002) 5 (31,5) Yes Yes Yes
Tsuboi et al. (2001) 13 (12) Yes Yes Yes
Gearing et al. (1994) 2 No No -
Fearnley et al. (1991) 1 No No -
Mori et al. (1986) 1 No No -
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be fully ascertained, bearing in mind that LBs might represent
an incidental finding without any clinical significance (Tsuboi
et al., 2001). It is also worth noting that PSP cases with
LBs previously reported in the literature had often received
clinical diagnosis other than PSP (Keith-Rokosh and Ang,
2008).
The second patient developed VH, a common finding in
patients with underlying LB pathology considered to be due
to neuronal dysfunction specific to α-synuclein accumulation
(Popescu et al., 2004). The brain of this patient contained isolated
LBs in the amygdala and in the cingulated cortex. By contrast,
the brain from the first patient showed a higher density of
LBs in the amygdala but she did not developed VH. Although
infrequently observed, VH may also be present in PSP brains
without LBs (Bertram andWilliams, 2012). The patient described
by Compta et al. (2009) with clinical features of PD and VH
andwidespread phosphorylated tau deposits consistent with PSP,
included severe tau pathology in the hippocampus and amygdala
in the absence of LBs, therefore leading to the suggestion that the
location of pathological lesions in the brain is the most important
factor determining VH (Compta et al., 2009). Although it is
tempting to speculate that the clinical heterogeneity seen in
parkinsonian disorders may reflect the occurrence of combined
pathology, it is very likely that the distribution of pathological
deposits also is a key underlying factor in determining clinical
differences.
The main limitation of the present study is represented
by the fact that LBs were only found in two PSP patients,
therefore minimizing potential clinico-pathological correlates.
Nevertheless, it should be stressed that our data unequivocally
showed the presence of tau and α-synuclein co-expression
within single TH-positive neurons in both the SNc and
the LC nuclei. Earlier data from the literature have
reported tau and α-synuclein co-localization in very few
neurons of the nucleus basalis of Meynert and in the
LC, whereas this co-expression was never observed in
the SNc (Uchikado et al., 2006). Furthermore, a kind of
‘‘globular’’ α-synuclein aggregates in just a few neurons with
phosphorylated tau-positive cytoplasm at the level of the pontine
tegmentum has also been reported elsewhere (Tsuboi et al.,
2001).
The colocalization of tau and α-synuclein in the same neuron
suggests an association between tau and α-synuclein aggregation
that could be mediated by tau inclusions that promote the
fibrillation of α-synuclein to form LBs in regions with abundant
tau lesions (Popescu et al., 2004). Evidence of an interaction
between tau and α-synuclein at a biochemical level has also been
found. Brain α-synuclein accumulation determined by western
blotting was above normal levels in the substantia nigra of
some patients with PSP (Tong et al., 2010). Experimental studies
have demonstrated that coincubation of tau and α-synuclein
synergistically promotes fibrillization of both proteins in LBs
(Giasson et al., 2003) and interactions between α-synuclein
and tau at the cellular level cause disruption of cytoskeletal
organization, axonal transport defects and aberrant synaptic
organization that contribute to neuronal dysfunction and death
(Roy and Jackson, 2014). Moreover, it is worth noting that
protein aggregation develops naturally with age, although the
question of whether this aggregation is cause or consequence
of normal -or abnormal- aging remains to be fully elucidated
(Cuanalo-Contreras et al., 2013).
Double-label studies demonstrated that in Pick disease -a 3R
tauopathy-, LBs usually colocalize with tau-positive Pick bodies
(Popescu et al., 2004). Regarding AD cases, in which tau is
composed of a mixture of 3R and 4R tau isoforms, LBs typically
colocalize with tau-positive neurofibrillary tangles especially in
neuronal populations vulnerable to both neurofibrillary tangles
and LBs, such as those in the LC and basal nucleus of Meynert
(Ishizawa et al., 2003). Moreover, a potential α-synuclein and tau
co-aggregation in neurons and neuritis from the olfactory bulb
in AD patients has been more recently reported (Fujishiro et al.,
2008).
We conclude that the presence of LBs in PSP patients
may be viewed as a secondary phenomenon probably
reflecting a synergistic effect between α-synuclein and
tau. This phenomenon is more evident in populations of
catecholaminergic neurons such as dopaminergic neurons in the
SNc and noradrenergic neurons at the level of the LC. Finally,
bearing in mind the low incidence of α-synuclein and tau co-
localization in our series of PSP patients, we strongly believe that
a direct clinical correlate to be induced by the co-aggregation of
these two misfolded proteins is very unlikely.
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